Cervical Cancer, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Conditions
Brief summary
RATIONALE: Specialized radiation therapy, such as proton beam radiotherapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving proton beam radiation therapy together with cisplatin works in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer and positive lymph nodes.
Detailed description
PRIMARY OBJECTIVES: I. To determine the feasibility of proton beam radiotherapy in patients with cervical cancer and FDG-positive para-aortic lymph nodes. SECONDARY OBJECTIVES: I. To determine the incidence of acute toxicity of concurrent weekly cisplatin chemotherapy in addition to pelvic and para-aortic irradiation using proton radiotherapy with intracavitary brachytherapy in patients with carcinoma of the uterine cervix with pelvic and para-aortic nodal involvement as demonstrated by FDG-PET. II. To assess late complications from irradiation using proton beam therapy in place of conventional photon beam therapy. III. To compare the dose distribution to tumor and surrounding normal structures using DVHs (Dose Volume Histograms) generated from the proton plan used to treat the patient and the photon plan generated for comparison purposes. IV. To evaluate whether there is a benefit to concurrent weekly cisplatin chemotherapy in addition to pelvic and para-aortic proton beam radiotherapy with intracavitary brachytherapy as evidenced by time to local failure, time to distant failure, time to other failures and overall survival in patients with carcinoma of the uterine cervix with pelvic and para-aortic nodal involvement as demonstrated by FDG-PET. OUTLINE: Patients undergo CT, MRI, or FDG-PET imaging scans for radiotherapy treatment planning. Patients then undergo external proton beam radiotherapy once daily, 5 times per week, for up to 9 weeks. Patients also receive cisplatin IV once weekly for 6 weeks during radiotherapy. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 2 years and then annually for 3 years.
Interventions
RADIATIONproton beam radiation therapy
Undergo external proton beam radiation
DRUGcisplatin
Given IV
Sponsors
Abramson Cancer Center at Penn Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion * Patients must have histologically documented carcinoma of the uterine cervix * FIGO Stage IB to IVA * Patients must have no distant metastases apart from positive lymph nodes by FDG PET * Patients must have a Karnofsky Performance Status of \>= 60 * Treatment plan includes cisplatin and patient has no medical contraindications to the administration of cisplatin * Adequate bone marrow function: WBC \>= 3000/mm\^3; platelets \>= 75,000 mm\^3 * Adequate renal function: creatinine =\< 2.0 mg/dl (urinary diversion is permitted to improve renal function) * Patients must have bilirubin =\< 1.5 mg/dl * Ability to understand and the willingness to sign a written informed consent document Exclusion * FDG PET Scan evidence of distant disease * No prior surgery for treatment of disease other than exploratory laparotomy or biopsy will be allowed * No previous systemic chemotherapy will be allowed * No prior pelvic radiation therapy is permitted other than transvaginal irradiation to control bleeding will be allowed * Women of childbearing potential who have a positive result on screening serum pregnancy test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility | — |
| Acute toxicity, as assessed by NCI CTC Version 4.0 | Within 60-90 days following completion of proton therapy |
Secondary
| Measure | Time frame |
|---|---|
| Late toxicity, as assessed by RTOG/EORTC late morbidity scoring system | More than 90 days after starting therapy |
| Clinical efficacy (time to local failure, time to distant failure, overall survival) | — |
Outcome results
None listed